ArticleBMC medicine2020
Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic.
Article in BMC medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 117 citations in OpenAlex.
- Comparing Ovulation Outcomes of Letrozole-Tamoxifen-Estradiolwith and without Vitamin E in Infertile Women with PolycysticOvary Syndrome: A Double-Blind, Randomized Clinical Trial.International journal of fertility & sterility · 2026Article
- Global Burden of Polycystic Ovary Syndrome: A Systematic Analysis of Pre- and Post-Pandemic Trends from the 2021 Global Burden of Disease Study (1990-2021).International journal of women's health · 2026Article
- Impact of obesity on proteomic profiles of follicular fluid-derived small extracellular vesicles: A comparison between PCOS and non-PCOS women.Journal of ovarian research · 2025Article
- Changes in the global burden of polycystic ovary syndrome from 1990 to 2021.Reproductive health · 2025Article
- Serological Evaluation of Anti- FSH Antibody and Anti- LH antibody In Iraqi Women with Polycystic Ovarian Syndrome.F1000Research · 2025Article
- The Impact of the COVID-19 Pandemic on Health and Health Care Experience in Those With Polycystic Ovary Syndrome.International journal of women's health · 2025Article
- Unraveling the pathogenic interplay between SARS-CoV-2 and polycystic ovary syndrome using bioinformatics and experimental validation.Scientific reports · 2024Article
- Stress responses to bacterial and viral mimetics in polycystic ovary syndrome model rats.Brain, behavior, & immunity - health · 2024Article
- COVID-19 and persistent symptoms: implications for polycystic ovary syndrome and its management.Frontiers in endocrinology · 2024Review
- Article
- COVID-19 retreats and world recovers: A silver lining in the dark cloud.Health care science · 2023Review
- Gender Differences in Response to COVID-19 Infection and Vaccination.Biomedicines · 2023Review
- Addressing Chronic Gynecological Diseases in the SARS-CoV-2 Pandemic.Medicina (Kaunas, Lithuania) · 2023Observational
- Real-world demographic patterns of users of a digital primary prevention service for diabetes.Cardiovascular endocrinology & metabolism · 2023Article
- Review
- Capability, Opportunity, and Motivation-Identifying Constructs for Increasing Physical Activity Behaviours in Women with Polycystic Ovary Syndrome (PCOS).International journal of environmental research and public health · 2023Article
- The Implication of Mechanistic Approaches and the Role of the Microbiome in Polycystic Ovary Syndrome (PCOS): A Review.Metabolites · 2023Review
- Observational
- The causal association between polycystic ovary syndrome and susceptibility and severity of COVID-19: a bidirectional Mendelian randomization study using genetic data.Frontiers in endocrinology · 2023Article
- Metformin is associated with reduced COVID-19 severity in patients with prediabetes.Diabetes research and clinical practice · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn women of reproductive age, polycystic ovary syndrome (PCOS) constitutes the most frequent endocrine disorder. Women with PCOS are considered to typically belong to an age and sex group which is at lower risk for severe COVID-19. MAIN BODY: Emerging data link the risk of severe COVID-19 with certain factors such as hyper-inflammation, ethnicity predisposition, low vitamin D levels, and hyperandrogenism, all of which have known direct associations with PCOS. Moreover, in this common female patient population, there is markedly high prevalence of multiple cardio-metabolic conditions, such as type 2 diabetes, obesity, and hypertension, which may significantly increase the risk for adverse COVID-19-related outcomes. This strong overlap of risk factors for both worse PCOS cardio-metabolic manifestations and severe COVID-19 should be highlighted for the clinical practice, particularly since women with PCOS often receive fragmented care from multiple healthcare services. Comprehensively informing women with PCOS regarding the potential risks from COVID-19 and how this may affect their management is also essential.
conclusionDespite the immense challenges posed by the COVID-19 outbreak to the healthcare systems in affected countries, attention should be directed to maintain a high standard of care for complex patients such as many women with PCOS and provide relevant practical recommendations for optimal management in the setting of this fast moving pandemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.